# A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers

> **NCT06013163** · PHASE1 · UNKNOWN · sponsor: **Empros Pharma AB** · enrollment: 20 (estimated)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** Xenical® vs EMP 22
- **DRUG:** EMP 22 vs Xenical®
- **DRUG:** EMP 16 vs Xenical®

## Key facts

- **NCT ID:** NCT06013163
- **Lead sponsor:** Empros Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-22
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06013163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06013163, "A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06013163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*